Remove Doctors Remove Long-Term Care Facilities Remove Research Remove Vaccine
article thumbnail

COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines | 2020-12-17

The Pharma Data

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52
article thumbnail

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

The Pharma Data

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccine 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biden Will Ask Americans to Wear Masks for 100 Days

The Pharma Data

Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe.

article thumbnail

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

The Pharma Data

” Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe. Grossman School of Medicine, told the Times.

article thumbnail

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. have reached record highs. It remains under review by the FDA.

article thumbnail

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic,” said David A. Ricks, Lilly’s chairman and CEO. patients who recovered from COVID-19. .